DERMATA THERAPEUTICS INC DRMAW 深 滬
已收盤 08-07 16:00:00 美东时间
0.0066
-0.001
-12.00%
華盛通- 最 高0.0066
- 今 開0.0066
- 成交量 1.11万股
- 最 低 0.0066
- 昨 收 0.0075
- 總市值 0
- 52周最高 0.029
- 市盈率 靜 --
- 換手率 Infinity.00%
- 52周最低 0.0066
- 委 比 -82.92%
- 總股本 --
- 歷史最高 1.70
- 量 比 3.12
- 振 幅 0.00%
- 歷史最低 0.005
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dermata Therapeutics Secures Australian Patent Acceptance For Bioneedle System In Dermal Fillers
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has allowed and issued patents in the US, Australia, and Japan covering
04-02 20:38
Dermata Therapeutics Announces Private Placement Up To $12.4M
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and
2025-12-24 21:01
Dermata Therapeutics Announces Australian Patent Office Accept Patent Application For Spongilla Technology Combination As Method For Treating Acne
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -- Dermata expects to launch a new once-weekly, Over-the-Counter (OTC)
2025-10-02 20:02
Dermata Therapeutics Announces Strategic Pivot To Prioritize Development And Distribution Of OTC Pharmaceutical Dermatology Focused Products
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the development and
2025-09-10 20:09
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI™ is the first once-weekly topical product ...
2025-03-27 20:00
